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Introduction: The global burden of disease (GBD) studies 
have derived detailed and comparable epidemiological and 
burden of disease estimates for schizophrenia. We report 
GBD 2016 estimates of schizophrenia prevalence and bur-
den of disease with disaggregation by age, sex, year, and for 
all countries. Method: We conducted a systematic review to 
identify studies reporting the prevalence, incidence, remis-
sion, and/or excess mortality associated with schizophrenia. 
Reported estimates which met our inclusion criteria were 
entered into a Bayesian meta-regression tool used in GBD 
2016 to derive prevalence for 20 age groups, 7 super-regions, 
21 regions, and 195 countries and territories. Burden of dis-
ease estimates were derived for acute and residual states of 
schizophrenia by multiplying the age-, sex-, year-, and loca-
tion-specific prevalence by 2 disability weights representative 
of the disability experienced during these states. Findings: 
The systematic review found a total of 129 individual data 
sources. The global age-standardized point prevalence of 
schizophrenia in 2016 was estimated to be 0.28% (95% 
uncertainty interval [UI]: 0.24–0.31). No sex differences 
were observed in prevalence. Age-standardized point preva-
lence rates did not vary widely across countries or regions. 
Globally, prevalent cases rose from 13.1 (95% UI: 11.6–14.8) 
million in 1990 to 20.9 (95% UI: 18.5–23.4) million cases in 
2016. Schizophrenia contributes 13.4 (95% UI: 9.9–16.7) 
million years of life lived with disability to burden of disease 
globally. Conclusion: Although schizophrenia is a low preva-
lence disorder, the burden of disease is substantial. Our mod-
eling suggests that significant population growth and aging 
has led to a large and increasing disease burden attributable 
to schizophrenia, particularly for middle income countries.
Key words:  mental health/schizophrenia/epidemiology/
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Introduction
Schizophrenia is a complex mental disorder, with typi-
cal onset in late adolescence or early adulthood. Despite 
intensive and ongoing research, outcomes from best-
practice treatment are often suboptimal. A  systematic 
review based on 50 outcome studies reported that the 
median proportion of people with schizophrenia who 
met clinical and social recovery criteria was only 13.5%.1
In addition to poor recovery outcomes, those liv-
ing with schizophrenia have a significantly reduced life 
expectancy.2 High excess mortality is found across all 
age groups3 and this differential mortality gap between 
those with and without schizophrenia may have increased 
in recent decades.4 Schizophrenia has also been linked 
to higher rates of comorbid illnesses and most excess 
deaths are due to underlying physical illnesses, especially 
chronic diseases such as coronary heart disease, stroke, 
type II diabetes, respiratory diseases, and some cancers.2 
Unnatural causes, including suicide, account for less than 
15% of excess deaths.3
Schizophrenia is a disorder with a relatively low prev-
alence. A  systematic review conducted by Saha et  al5 
demonstrated a median population period prevalence of 
3.3 per 1000. Developing health services for schizophre-
nia will require robust and informative epidemiological 
estimates, including estimates of the number of people 
living with schizophrenia in a given population and how 
Downloaded from https://academic.oup.com/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sby058/4995547
by University of Queensland user
on 22 June 2018
Page 2 of 9
F. Charlson et al
these have changed over time—estimates that are cur-
rently unavailable for schizophrenia. Recent innovations 
in statistical modeling, as part of the global burden of 
disease (GBD) studies, have allowed for the derivation of 
detailed and comparable epidemiological estimates for 
schizophrenia by age, sex, geography, and year.
Quantification of the burden of disease attributable 
to schizophrenia was first undertaken in the GBD Study 
carried out by the World Health Organization in 1990,6 
with an update in 2004.7 Recent iterations of the GBD 
Study, conducted by the Institute for Health Metrics 
and Evaluation at the University of Washington, have 
expanded the number of included disorders and made 
significant methodological improvements. The most 
recent iteration is GBD 2016.8
The core metric used to measure disease burden in 
GBD is the disability adjusted life year (DALY). One 
DALY is equivalent to 1 healthy year of life lost to a dis-
ease. The DALY is calculated by summing the years of life 
lived with disability (YLDs) and years of life lost (YLLs) 
to premature mortality for a given disease. This inclusion 
of disability when measuring disease burden has been 
particularly influential in highlighting schizophrenia as 
a leading contributor to disease burden. Despite being a 
low prevalence disorder, schizophrenia ranked the 12th 
most disabling disorder among 310 diseases and injuries 
globally in 2016.9
The GBD 2016 study provides an overview of the epide-
miology and burden of disease attributable to 333 diseases 
and injuries; however, detailed findings for schizophrenia 
have not been previously published. We report GBD 2016 
estimates of schizophrenia prevalence and burden of dis-
ease with disaggregation by age, sex, year, and country. 
Additionally, we will explore how changes in population 
growth and ageing have impacted on the epidemiology of 
schizophrenia over time, and how burden of disease var-
ies by geography and development status. The availability 
of global epidemiological data on schizophrenia, which 
underpins this work, will also be presented in detail.
Methods
In GBD 2016, schizophrenia was defined according 
to diagnostic criteria proposed in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR: 
295.10–295.30, 295.60, 295.90)10 or the International 
Classification of Diseases (ICD-10: F20.0-F20.3 
F20.5-F20.9).11 Other psychotic disorders, including 
those due to a general medical condition or substance 
induced cases, were not included.
Estimation of Years Lived With Disability
Identifying Available Data.  We conducted a systematic 
review of the literature to identify studies reporting the 
prevalence, incidence, remission, and/or excess mortality 
associated with schizophrenia. Comprehensive litera-
ture reviews have been conducted for studies reporting 
on the incidence,12 prevalence,5 remission,1 and excess 
mortality4 of schizophrenia published between 1965 
and 2002. These existing reviews formed the starting 
point of our search. All included studies were reviewed 
for eligibility and the systematic literature searches were 
replicated to identify any subsequent data published 
up to 2016. Electronic databases (Medline, PsycInfo, 
and EMBASE) were searched using the following 
search string: (Schizophrenia[Title]) AND (((((epi-
demiology) OR epidemiology[MeSH Terms]) OR 
prevalence[Title/Abstract]) OR incidence[Title/Abstract]) 
OR mortality[Title/Abstract]) OR remission[Title/
Abstract])). A  secondary manual search of review arti-
cles, texts, and key documents was conducted to identify 
any additional studies not found in the database search. 
The final stage was to email experts in the field seek-
ing information on any further data, including that not 
yet published. The search methodology adhered to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.13 All GBD 2016 
analyses adhered to the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER).14
Studies found in both the previous reviews and the cur-
rent search were evaluated against a set of inclusion cri-
teria. To be included in our GBD 2016 analysis, studies 
needed to: (1) make use of a cross-sectional or longitu-
dinal design, the latter with a minimum follow up period 
of two years to allow sufficient time for observation of 
outcomes; (2) report estimates of prevalence, incidence, 
remission, and/or excess mortality for schizophrenia; 
or provide sufficient data for these to be estimated; (3) 
utilize the DSM or ICD diagnostic criteria; (4) report 
estimates of point (current/past month) or past year prev-
alence (lifetime estimates were excluded as these are at an 
increased risk of recall bias15–18); (5) report estimates of 
incidence in the form of hazard rates with person years 
of follow up as the denominator; (6) report estimates of 
excess mortality in the form of relative risks or standard-
ized mortality ratio; and (7) make use of a sample which 
could be considered representative of the community, 
region, or country under study (inpatient and clinical 
samples were excluded, except for estimates of mortal-
ity). Publications were restricted to those published from 
1980 onwards. A  list of epidemiological data sources 
by type and country can be found in the online supple-
mentary material. Additionally, a suite of visualization 
tools is available to explore GBD data inputs and outputs 
(http://www.healthdata.org/gbd/data-visualizations).
Modeling Prevalence.  Reported estimates of preva-
lence, incidence, remission, and excess mortality were 
entered in DisMod-MR 2.1 for analysis. DisMod-MR 2.1 
is a Bayesian meta-regression tool used in GBD 2016 to 
meta-analyze prevalence.19,20 It is an updated version of 
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DisMod MR 1.0 used in GBD 201021 and makes use of an 
established incidence–prevalence–mortality mathematical 
model as well as a log rate model to estimate prevalence. 
DisMod-MR 2.1 estimated prevalence globally for 23 age 
groups, 6 time points, 7 super-regions, 21 regions, and 195 
countries and territories. This includes subnational loca-
tions in the United Kingdom, China, Mexico, Indonesia, 
Brazil, India, Japan, Kenya, Sweden, South Africa, Saudi 
Arabia, and the United States. If  no raw epidemiological 
data were available for a particular location, data from 
surrounding locations were used to estimate prevalence. 
Within DisMod-MR 2.1, regions and super-regions were 
defined according to GBD 2016’s classification of broad 
geographic regions or continents. Each region was made 
up of 2 or more countries, grouped according to child/
adult mortality rates and major causes of death. The esti-
mation of prevalence was conducted as a full “cascade” 
ie, in sequence from global, to super-regional, to regional, 
and finally, country-level and where relevant sub-national-
level estimations. This approach ensured that the modeled 
prevalence output was consistent at all levels of the cas-
cade. At the global level, reported estimates of prevalence, 
incidence, remission, and excess-mortality were used to 
estimate super-regions priors using a mixed effects non-
linear regression model. The super-region modeled output 
was generated using these priors passed down from the 
global fit. These were used to generate regional-level esti-
mates which in turn informed country- and subnational-
level estimates. Additional information on DisMod-MR 
2.1 can be accessed elsewhere.19,20
In order to facilitate modeling, a range of simplifying 
assumptions was used to guide the DisMod-MR 2.1 anal-
ysis for schizophrenia. We assumed zero incidence before 
age 10 and after age 80. These age limits were corrobo-
rated with expert feedback as well as the age range of 
the incidence data obtained from our systematic review. 
Remission was defined as complete clinical remission and 
was restricted to a maximum annualized remission rate 
of 0.04 as guided by the raw data.
Covariates.  We identified sources of variability in the 
raw data and used covariates during the modeling proc-
ess to test whether these sources of variability were being 
driven by measurement error; however, none of the 
study-level covariates had a statistically significant effect 
on the prevalence model. Examples of variables tested in 
DisMod modeling include diagnostic type (designed to 
create a crosswalk between prevalence based on unknown 
diagnostic criteria to prevalence based on the ICD/DSM 
criteria), and sample coverage (designed to create a cross-
walk between prevalence derived from samples with com-
munity coverage and prevalence from samples with more 
representative regional/national coverage).
Disability Weights. YLDs were estimated for schizo-
phrenia by multiplying the DisMod MR 2.1 age-, sex-, 
year-, and location-specific prevalence by 2 disability 
weights representative of the disability experienced dur-
ing acute and residual states of schizophrenia. An acute 
state predominantly involved the presentation of positive 
symptoms of schizophrenia (eg, delusions, hallucinations, 
and thought disorder). A  residual state predominantly 
involved negative symptoms (eg, flat affect, loss of inter-
est, and emotional withdrawal).22 These 2 health states 
were selected to capture differences in disability caused 
by changes in the severity of symptoms of schizophre-
nia. They were defined according to the DSM-IV-TR 
description of this disorder.10 Disability weights were esti-
mated using community-based surveys in Bangladesh, 
Indonesia, Peru, the United Republic of Tanzania, and 
the United States of America (conducted for GBD 2010), 
and Hungary, Italy, Sweden, and the Netherlands (con-
ducted for GBD 2013), as well as an open-access internet 
survey available in English, Spanish, and Mandarin.20,23–26 
Overall, disability weight surveys included lay descrip-
tions representing all nonfatal outcomes from the diseases 
and injuries in GBD. Lay descriptions were presented to 
participants in a pair-wise comparison method, ie, partici-
pants were provided with random pairings of lay descrip-
tions and asked to nominate which lay description they 
considered the healthier. Their responses were anchored 
on a scale of 0 (healthy) to 1 (death) using additional 
questions comparing the benefits of lifesaving and disease 
prevention programs for a selection of health states.20 The 
estimated disability weights for acute and residual states 
of schizophrenia were 0.778 (0.606–0.900) and 0.588 
(0.411–0.754), respectively. Acute schizophrenia carries 
the highest disability weight of all disorders in GBD.25
Severity Splits. To capture differences in disability 
caused by changes in the severity of symptoms of schiz-
ophrenia, disability weights were determined for 2 health 
states (acute and residual states) defined according to 
the DSM-IV-TR10 description of this disorder.9 We con-
ducted a separate systematic literature review to identify 
survey data reporting on the proportion of schizophre-
nia cases in an acute and residual state, respectively.22 
Meta-Xl 1.2, a Microsoft Excel add in for meta-analysis 
was used to pool data from 6 studies into the total pro-
portion of schizophrenia cases experiencing acute and 
residual states.22 Pooled health state-specific proportions 
were used to distribute total schizophrenia prevalent 
cases (estimated by Dismod MR 2.1) across each health-
state specific disability weight. Overall, 62.7% (28.8%–
91.4%) of schizophrenia cases fell within an acute state 
and 37.3% (8.6%–71.2%) fell within a residual state. 
More information on the meta-analysis of health-state 
specific proportions is presented in the online supplemen-
tary material.
Comorbidity Adjustments. An adjustment for comor-
bidity was necessary due to the fact that the burden 
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attributable to GBD causes was estimated separately. The 
co-occurrence of different diseases and injuries was sim-
ulated in populations of 40 000 within each stratification 
of location, age, sex, and year. The individuals within 
each population were hypothetically exposed to the 
independent probability of having any combination of 
sequelae included in GBD 2016. The comorbidity adjust-
ment estimated the difference between the average disa-
bility weight of individuals experiencing one sequela and 
the multiplicatively combined disability weight of those 
experiencing multiple sequelae. The average comorbidity 
correction estimated for each sequela was applied to the 
respective location-, age-, sex-, and year-specific YLD. 
Further information is available elsewhere.9
Estimation of DALYs
DALYS are estimated by the sum of YLDs and YLLs 
for an overall measure of disease burden. Although it 
is widely acknowledged that schizophrenia is associated 
with premature mortality, GBD 2016 did not attribute 
any cause-specific deaths to schizophrenia per se, thus 
there were no YLLs estimated and DALYs were equiv-
alent to YLDs.
95% uncertainty intervals (UI) were propagated from 
all levels of the burden estimation methodology based on 
the 25th and 75th ordered draw of the modeling process. 
Age-standardized rates were computed using the world 
standard population developed for the GBD study.27
Results
Data Availability
The systematic review found a total of 129 individual data 
sources which could be included in the DisMod modeling 
for GBD 2016. These included 64 prevalence, 37 mortality, 
5 remission, and 30 incidence studies from 106 geograph-
ical locations (including both national and subnational 
locations) giving a total of 756 individual data points (sup-
plementary table S1). Much of epidemiological data came 
from high income countries—notably, Denmark, Japan, 
and Sweden (figure 1). China and India also had a rela-
tively high amount of epidemiological data representative 
at the provincial-level; however, data from other low- and 
middle-income countries was very sparse (figure 1). Further 
details of input data sources can be found online at http://
ghdx.healthdata.org/gbd-2016/data-input-sources.
Prevalence
The global age-standardized point prevalence of schiz-
ophrenia in 2016 was estimated to be 0.28% (95% UI: 
0.24–0.31). Figure  2 demonstrates an onset of schizo-
phrenia in adolescence and young adulthood with preva-
lence peaking at around 40 years of age with a decline in 
the older age groups. No sex differences were observed in 
prevalence.
Age-standardized point prevalence rates to do not 
vary widely across countries or regions (figure  3 and 
Fig. 1. Map of epidemiological data points by global burden of disease region.
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supplementary table S2); however, data sources from sev-
eral subnational surveys in China have resulted in consist-
ently higher modeled estimates for China, which showed 
the highest age-standardized prevalence of schizophrenia 
(0.42% [95% UI: 0.38–0.48]; figure 3). The prevalence of 
schizophrenia in the Netherlands was higher than that of 
other countries within Western Europe (0.36% [95% UI: 
0.32–0.40]). Some of the lowest mean prevalence rates 
were found in the sub-Saharan Africa and North Africa/
Middle East regions.
Globally, prevalent cases rose from 13.1 (95% UI: 11.6–
14.8) million in 1990 to 20.9 (95% UI: 18.5–23.4) million 
cases in 2016. An estimated 70.8% (or 14.8 million) of 
these cases occurred in the 25–54 years age group.
Incorporating regional population sizes to estimate 
prevalent cases shows that East Asia and South Asia 
carry the largest number of cases, approximately 7.2 (95% 
UI: 6.4–8.1) million and 4.0 (95% UI: 3.5–4.5) million, 
respectively in 2016 (figure  4). Oceania had the lowest 
number of cases, around 28 000 (95% UI: 24 000–32 000), 
and the combined sub-Saharan African regions experi-
enced approximately 1.3 (95% UI: 1.1–1.5) million cases 
in 2016.
East Asia experienced the largest absolute increase in 
prevalent cases from approximately 4.9 million cases in 
1990 to 7.2 million cases in 2016. However, the largest 
percentage increases over the 1990 to 2016 period took 
place in Eastern sub-Saharan Africa (126%) and North 
Africa/Middle East (128%). These increases were attrib-
utable to the significant population growth during this 
period. Prevalent cases by country and year can be found 
in supplementary table S2).
Burden of Disease Estimates
The schizophrenia burden, as estimated by GBD 2016, is 
attributed to a disability-associated burden (ie, YLDs). 
Schizophrenia contributes 13.4 (95% UI: 9.9–16.7) mil-
lion YLDs to burden of disease globally, equivalent to 
1.7% of total YLDs globally in 2016.
As with prevalence, the peak disease burden is 
observed at around 30–40 years of  age. A comparable 
burden is seen in males and females. DALYs by country 
and region for 2016 can be found in the supplementary 
table S3.
Observing differences in DALYs according to income 
status demonstrates that the large burden of schizo-
phrenia experienced in lower- and upper-middle income 
countries is around 4 times the burden experienced by 
high-income countries (figure 5). This is largely attribut-
able to the burgeoning populations of low- and middle-
income countries.
Discussion
This study estimates that 21 million people are living with 
schizophrenia, globally, and this figure is set to continue 
to rise with population ageing and growth. The majority 
of these people live in low- and middle-income countries, 
coinciding with the highest treatment gaps of around 
90% in most low- and middle-income countries.28
Saha et al5 found 132 prevalence studies that met their 
inclusion criteria. Our study had more stringent inclusion 
criteria (eg, prevalence estimates were required to be rep-
resentative of the general population, rather than from 
clinical samples) but included the full range of epidemi-
ological parameters (prevalence, incidence, remission, 
and mortality) and found 129 studies, 64 of which were 
studies reporting prevalence. Saha et al5 found a pooled 
mean point prevalence of 0.60% (SD 0.6); our study esti-
mates were significantly lower at 0.28% but with narrow 
uncertainty (95% UI: 0.24–0.31); however, comparisons 
with our findings are difficult due to methodological 
differences.
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Fig. 2. Global mean prevalence rates (with 95% uncertainty interval) by age and sex, 2016.
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Our study draws attention to the lack of high qual-
ity, representative data available on the epidemiology of 
schizophrenia. Very limited data meeting our inclusion 
criteria were found in low- and middle-income coun-
tries. High-quality studies of low prevalence disorders 
are very challenging to conduct, particularly in resource 
constrained settings. DisMod-MR 2.1 is able to impute 
estimates for countries with missing data until such a 
time countries are able to conduct prevalence surveys. 
Although schizophrenia is a low prevalence disorder, the 
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Fig. 4. Prevalent schizophrenia cases by year and region, 1990 and 2016.
Fig. 3. Map of age-standardized prevalence by country, 2016.
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burden of disease is undeniably substantial. Our mod-
eling shows that age-specific prevalence remains largely 
consistent over time and across countries, and signifi-
cant population growth and ageing has led to a large and 
increasing disease burden attributable to schizophrenia, 
particularly for middle income countries. The early onset 
of the disorder, the low remission rates and the high dis-
ability weights all contribute to excessive burden associ-
ated with this disorder.
A few countries demonstrated notable differences. Age-
standardized prevalence and YLD rates attributable to 
schizophrenia were significantly higher in China than the 
global average. Earlier iterations of GBD,29 and commu-
nity-based surveys30–32 have also estimated higher preva-
lence and burden of schizophrenia in China, suggesting 
this finding may not be driven by variation in study meth-
odology by location. Within the European region, The 
Netherlands demonstrated higher prevalence, a find-
ing supported by both prevalence and incidence studies 
within our dataset. Like Saha et al,5 we also found lower 
prevalence estimates from the least developed countries.
Consistent with the systematic review by Saha et al,5 
we also found no apparent sex difference in prevalence. 
One notable exception of this is the lower prevalence 
of schizophrenia among males compared to females in 
China. The higher suicide rate among males with schizo-
phrenia in China may partially contribute to the reversed 
sex effect seen in China relative to other global regions.33 
Previous research suggests that women develop schizo-
phrenia later than men34; however, this was not observed 
in our models. The availability of more age- and sex-
specific data points is needed to inform these patterns. 
The disability measured in GBD captures the morbid-
ity attributable to schizophrenia. Schizophrenia is also 
associated with significant impairments in psychosocial 
function; people with schizophrenia are more likely to 
be unemployed, homeless, living in poverty, having dif-
ficulties keeping up with household and self-care tasks, 
and relying on ongoing support from family carers and 
available mental health services. The largest burden from 
schizophrenia is in the 25–54 year age group, where indi-
viduals are most likely to be economically productive. 
This results in significant economic deficits due to losses 
in productivity by individuals and their families, out-of-
pocket costs for treatment, and considerable burdens on 
health and welfare systems.35
Limitations
The most significant limitation in this study was the 
sparsity of data, particularly in low- and middle-income 
countries. There may have been insufficient data to cap-
ture true variations across geography, sex, and time. There 
is a need for more epidemiological research on schizo-
phrenia to inform and improve future burden of disease 
estimates, including more data to inform the disability 
weights and health states for schizophrenia. Further lim-
itations related to the GBD studies have been discussed 
elsewhere.8
A limitation of GBD 2016 is that it did not attribute 
any cause-specific deaths to, and thus no YLLs were 
estimated for, schizophrenia. This is due to the relative 
absence of schizophrenia being coded as the primary 
cause of death on medical certificates within vital reg-
istration systems. The causes of premature mortality of 
those suffering from schizophrenia are typically coded 
to injuries (eg, suicide) or other health conditions (eg, 
cardiovascular disease). However, it is well established 
that there is a substantial life expectancy gap between 
people living with schizophrenia and the general popu-
lation, and it would be wrong to interpret GBD findings 
as suggesting the absence of premature mortality due to 
schizophrenia and its comorbidities. The majority of the 
premature mortality is due to higher rates of comorbid 
physical health conditions, such as heart disease and res-
piratory disease.36 As discussed earlier, the psychosocial 
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and economic burdens of schizophrenia are also not cap-
tured in the disability weights used in GBD.
Implications
Improved nutrition, reproductive health, and control 
of  communicable disease have resulted in significant 
demographic changes, causing an increase in the rela-
tive contribution of  noncommunicable disease to the 
global disease burden.9 This is leading to an increase 
in the burden from mental disorders, including schiz-
ophrenia. Health systems in low- and middle-income 
countries need to prepare for this increase but existing 
evidence-based interventions have been poorly imple-
mented, with only 31% of  people with schizophrenia 
accessing treatment in low- and middle-income coun-
tries, where the overall mental disorders treatment gap 
is as high as 89%.37 This calls for an urgent scaling up of 
services to respond to serious mental disorders such as 
schizophrenia.
Conclusion
The burden of schizophrenia is increasing globally. 
Most of the burden is in low- and middle-income coun-
tries where infant and childhood mortality has declined, 
resulting in a greater proportion of the population living 
to the age group where the risk of schizophrenia is great-
est. Health systems in most countries are unprepared for 
this escalating burden and without action to scale-up 
services, a lack of effective treatment for this debilitat-
ing mental disorder will critically impact individuals and 
their families.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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